Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL562848 | 0.99 | MGLL (0.50) | MGLLTLR9CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL487779 | 0.82 | MGLL (0.57) | MGLLTLR9ALDH1A1HSP90AA1PKM | |
| SCHEMBL28418862 | 0.77 | MGLL (0.54) | MGLLTLR9ALDH1A1HSP90AA1PKM | |
| SCHEMBL8352899 | 0.77 | MGLL (0.77) | MGLLTLR9ALDH1A1HSP90AA1PKM | |
| SCHEMBL8612834 | 0.75 | MGLL (0.59) | MGLLTLR9ALDH1A1HSP90AA1PKM | |
| SCHEMBL44044 | 0.74 | MGLL (0.54) | MGLLALDH1A1HSP90AA1PKMNPSR1 | |
| SCHEMBL3873448 | 0.74 | MGLL (0.73) | MGLLTLR9ALDH1A1NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL44524 | 0.73 | MGLL (0.52) | MGLLALDH1A1HSP90AA1PKMNPSR1 | |
| Hydrochloric Acid SCHEMBL443354 | 0.73 | MGLL (0.52) | MGLLALDH1A1HSP90AA1PKMNPSR1 | |
| SCHEMBL3879458 | 0.73 | MGLL (0.71) | MGLLTLR9ALDH1A1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905537-B2 | Bifunction chemical epigenetic modifiers and methods of use | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4297795-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | Transfert Plus, Société en Commandite (CA) | 2024-01-03 | — | — | EP | disclosed |
| US-20210355476-A1 | BIFUNCTION CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2021-11-18 | — | — | US | disclosed |
| EP-3844190-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | Transfert Plus, S.E.C. (CA) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020037434-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | TRANSFERT PLUS, S.E.C. (CA) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019028426-A1 | BIFUNCTIONAL CHEMICAL EPIGENENTIC MODIFIERS AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-3380495-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | Transfert Plus, S.E.C. (CA) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017088058-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2017-06-01 | — | — | WO | disclosed |
| EP-2885318-A1 | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026283-A1 | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2014-02-20 | — | — | WO | disclosed |
| WO-2013013700-A1 | MULTIVALENT ANTIGEN-BINDING FV MOLECULE | AFFIMED THERAPEUTICS AG (DE) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012027493-A1 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-7727720-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7442506-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070178478-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20060160105-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060140858-A1 | Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) | IMMUNOMEDICS, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-20060121452-A1 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060140858-A1 | Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) | MAN2B2, FUCA1, PREP | MGLL 1987/4885TLR9 771/4885CYP1A2 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.